key: cord-0931365-jdut6yna
authors: Meyer, B.; Reimerink, J.; Torriani, G.; Brouwer, F.; Godeke, G.-J.; Yerly, S.; Hoogerwerf, M.; Vuilleumier, N.; Kaiser, L.; Eckerle, I.; Reusken, C.
title: Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT)
date: 2020-09-23
journal: nan
DOI: 10.1101/2020.09.21.20191288
sha: 37ead3a37fbc475a444bc520453bbab6d2532c9e
doc_id: 931365
cord_uid: jdut6yna

To understand SARS-CoV-2 immunity after natural infection or vaccination, functional assays such as virus neutralizing assays are needed. So far, assays to determine SARS-CoV-2 neutralizing antibodies rely on cell-culture based infection assays either using wild type SARS-CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety facilities and are difficult to standardize. Recently, a new surrogate virus neutralisation assay (sVNT) was described that uses the principle of an ELISA to measure the neutralization capacity of anti-SARS-CoV-2 antibodies directed against the receptor binding domain. Here, we performed an independent evaluation of the robustness, specificity and sensitivity on an extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples collected before 2020 and compared it to cell-based neutralization assays. We found a high specificity of 99.2 (95%CI: 96.9-99.9) and overall sensitivity of 80.3 (95%CI: 74.9-84.8) for the sVNT. Clinical sensitivity increased between early (<14 days post symptom onset or post diagnosis, dpos/dpd) and late sera (>14 dpos/dpd) from 75.0 (64.7-83.2) to 83.1 (76.5-88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3 (56.4-86.9) and 98.2 (89.4-99.9) for titres [≥]10 to <40 and [≥]40 to <160, respectively. Only samples with a titre [≥]160 were always positive in the sVNT. In conclusion, the sVNT can be used as an additional assay to determine the immune status of COVID-19 infected of vaccinated individuals but its value needs to be assessed for the specific context of use.

74.9-84.8) for the sVNT. Clinical sensitivity increased between early (<14 days post symptom 48 onset or post diagnosis, dpos/dpd) and late sera (>14 dpos/dpd) from 75.0 (64.7-83.2) to 83.1 49 (76.5-88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon 50 comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3 51 (56.4-86.9) and 98.2 (89.4-99.9) for titres ≥10 to <40 and ≥40 to <160, respectively. Only samples 52 with a titre ≥160 were always positive in the sVNT. 53

In conclusion, the sVNT can be used as an additional assay to determine the immune status of 54 COVID-19 infected of vaccinated individuals but its value needs to be assessed for the specific 55 context of use. 56

Introduction 57

In 2020, the world is facing an unprecedented global health crisis through the emergence of the 58 novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative 59 agent of the disease COVID-19. The pandemic spread of this virus immediately raised a demand 60 for serological assays to support clinical and public health management, e.g. to determine a 61 recent or past infection, to assess the level of (sub) population exposure and, to investigate 62 different types of immune response and levels of potential immunity against re-infection. 63

Seven months into the outbreak a plethora of serological assays is available 1 that allows the 64 routine detection of several classes of antibodies, i.e. IgM, IgG and IgA 2-5 . However, to 65 understand immunity after natural infection or vaccination, a functional analysis of the elicited 66 antibody responses, such as avidity for the most immunogenic viral antigens and virus 67 neutralizing activity, is of utmost importance 6 . 68

So far, assays to determine SARS-CoV-2 neutralizing capability of antibodies rely on handling of 69 wild type or pseudotyped viruses and use cell-culture based infection as a read-out. This requires 70 a biosafety level (BSL) 3 laboratory for wild type SARS-CoV-2, or a BSL-2 laboratory for 71 pseudotyped viruses such as vesicular stomatitis virus (VSV) or lentivirus-based systems. These 72 in-house assays are difficult to standardize across laboratories, especially in the absence of an 73 international standard, as assay characteristics vary depending on culture conditions, virus strains 74 and cell lines used. Furthermore, these assays are labour-intensive, require highly skilled 75 personnel, have a low throughput and results are only available after several days. 76 complaints that tested negative for a suspected Bordetella pertussis infection (n=16), patients 123 with an acute cytomegalovirus (n=10) or acute Epstein-Barr virus (n=10) infection as well as adult 124 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint (n=21) and child (n=50) patients who came for routine diagnostic purposes to the hospital (Table  125 1). The sensitivity panel included sera from 269 PCR-confirmed COVID-19 patients. Of these 126 sera, 92 were taken before and 177 after 14 dpos/dpd. Severity of disease ranged from 127 asymptomatic (n=3) to mild (non-hospitalized, n=92), severe (hospitalized, n=87) and ICU-128 admitted/deceased (hospitalized, n=54). For 33 patients the severity of disease was unknown 129 (Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. In this study, we validated an ELISA-based surrogate SARS-CoV-2neutralisation assay (sVNT) 189 using specificity and sensitivity panels as described above. Among the 259 samples in the 190 specificity panel we identified two samples, one among the blood donors and one in the cohort 191 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint with a recent non-CoV respiratory infection (HMPV infected) that were positive using the 192 manufacturer recommended cut-off of 20% reduction (%reduction: 97.2 and 21.6, respectively). 193

Both samples were tested in the VNT50 and did not show any SARS-CoV-2 neutralising activity. 194

Considering an alternative cut-off of 30% reduction, as proposed in a recent publication by the 195 manufacturer 7 , only the blood donor sample remained positive for blocking RBD binding to ACE2 196 ( Figure 1A ). This indicates a specificity of 99.2 (95% CI: 96.9-99.9) and 99.6 (95% CI: 97.5-99.9), 197 respectively (Table 2) . Table 3 ). Furthermore, we analysed the relationship 206 between the severity of COVID-19 disease and the clinical sensitivity of the sVNT as stronger 207 immune responses were observed in severe vs mild cases 14,15 . We observed that the assay 208 sensitivity increased with an increased disease severity, higher in hospitalised patients vs 209 outpatients, regardless of the time of sampling. During the acute phase (<14dpos/dpd) of the 210 infection, the clinical sensitivity in mild cases was 47.4% and increased to 70.7% and 100% in 211 severe and ICU/deceased patients, respectively ( Figure 1D and Table 3) . A similar observation 212 was made in samples collected ≥14 dpos/dpd, where sensitivity increased from 75.3% in mild 213 cases to 91.3% and 88.2% in severe and ICU/deceased cases, respectively ( Figure 1E and Table  214 3). The median %reduction in the sVNT increased with disease severity, but this increase was 215 only significant for mild vs severe and mild vs ICU/deceased cases both before and after 216 14dpos/dpd (Kruskal-Wallis test) ( Figure 1D and E). When considering the alternative cut-off of 217 30% reduction to determine positivity in the sVNT, the clinical sensitivity of the assay decreased 218 by 0-9%, but the overall picture remained unchanged (Table 3) . 219 220 As the novel assay is meant to be implemented as a surrogate assay for functional cell-based 221 serological methods that measure SARS-CoV-2 neutralising capacity of antibodies, we compared 222 the performance of the sVNT with the conventional VNT50 and PNT50 assays. The sVNT detected 223 blocking of ACE2 binding activity in nine of 50 sera of confirmed COVID-19 patients that did not 224

show SARS-CoV-2 neutralising activity in the cell-based assays (Table 3) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint sera with a titre in the range of ≥10 to <40 as well as 56/57 sera with a titre in the range of ≥40 to 226 <160 in the cell-based neutralisation assays showed blocking activity in the sVNT. This results in 227 an analytical sensitivity of 74.3 (95% CI: 56.4-86.9) and 98.2 (95% CI: 89.4-99.9) respectively 228 when compared to conventional in-house neutralisation assays. Only sera (n=116) with a titre of 229 ≥160 in the PNT50/VNT50 were always positive in the sVNT. The median %reduction in the four 230 titre subgroups significantly increased with rising PNT50/VNT50 titres from -2.6 (<10) to 36.0 (≥10 231 to <40), 75.6 (≥40 to <160) and 92.5 (≥160) (Kruskal-Wallis test) ( Figure 1C ). To further 232 investigate the correlation of PNT50/VNT50 titres with %reduction in the sVNT, a linear regression 233 analysis was performed using all sera for which an endpoint titre was available (n=154). We found 234 a moderate correlation between PNT50 and sVNT %reduction (R 2 = 0.4937, p>0.0001) ( Figure 2B ) 235 and a slightly better correlation for VNT50 titres (R 2 = 0.6548, p>0.0001) ( Figure 2C) . 236

We also compared overall clinical sensitivity and specificity of the assay between the two centres 238

where the study was conducted (UNIGE and RIVM). Specificity was comparable with only minor 239 differences between the two laboratories. In contrast, clinical sensitivity was markedly lower at 240 UNIGE compared to samples analysed at RIVM (Table 4 ). However, samples from late time points 241 dpos/dpd where underrepresented in the UNIGE sample set, giving a potential explanation for 242 this discrepancy. 243 244 Last, we investigated the interassay variance of the sVNT by testing a representative subset of 245 samples at least five times at different days. Similar coefficients of variation (%CV) were found in 246 both laboratories. We observed a very low %CV in samples with a mean %reduction > 90%, 247 ranging from 0.22 to 4.63 %CV. However, the %CV increased to 3.55-13.73 in samples with a 248 mean %reduction between 50-60% and to 10.39-20.39 in samples with a mean %reduction 249 around 30%. Samples with a mean %reduction <11% gave a high %CV between 67.33-216.38 250 (Table 5) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint after vaccination or natural infection. However, these type of assays are operated based on in-260 house protocols and lack standardization across laboratories 16-18 . We performed an independent 261 two-centre clinical evaluation of the GenScript cPass™ test, which is based on the principle of an 262 inhibition ELISA, to assess its value for routine diagnostics and as surrogate functional assay to 263 measure neutralizing capability in SARS-CoV-2 elicited antibody responses. the RBD or the S1 domain, but also against the S2 domain as well as against N 19 . While antibodies 284 directed against the N protein are most likely non-neutralizing, antibodies directed against the N-285 terminal domain of S1 (outside of the RBD) have shown neutralizing potential 20 . In addition, for 286 SARS-CoV-1 also antibodies directed at the S2 domain show neutralizing capabilities 21 . Although 287 S2 domain-mediated neutralisation remains to be confirmed for SARS-CoV-2, assessing the 288 neutralizing ability with the sVNT might indeed miss the presence of virus neutralizing capabilities 289 directed outside of the RBD. Furthermore, all of the sera that were reactive in the sVNT but not in 290 the VNT50/PNT50 were reactive in the Wantai total Ig ELISA that targets RBD as well (data not 291 shown). This indicates that the activity measured in the sVNT is likely due to antibodies directed 292 against the RBD but without a virus neutralising capacity that leads to at least 50% reduction of 293 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.21.20191288 doi: medRxiv preprint 

A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on 354 antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 359 Blocked by a Clinically Proven Protease Inhibitor

Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination 362 in a Cohort of Older Adults

A vesicular stomatitis virus replicon-based bioassay for 365 the rapid and sensitive determination of multi-species type I interferon

Identification of Clotrimazole Derivatives as Specific Inhibitors of 368

Vesicular stomatitis virus pseudotyped with severe acute respiratory 370 syndrome coronavirus spike protein

Differences in Antibody Kinetics and Functionality Between Severe and

Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using 380

Propagation-Defective Vesicular Stomatitis Virus Pseudotypes

Virological assessment of hospitalized patients with COVID-2019

A comparison of four serological assays for detecting anti-SARS-CoV-2 384 antibodies in human serum samples from different populations

A neutralizing human antibody binds to the N-terminal domain of the Spike 387 protein of SARS-CoV-2

A human SARS-CoV neutralizing antibody against epitope on S2 protein

Autoantibodies to angiotensin-converting 391 enzyme 2 in patients with connective tissue diseases

PhD. COVID-19-A theory of autoimmunity to

Duration of infectiousness and correlation with RT-PCR cycle 395 threshold values in cases of COVID-19

DPOS, days post onset of symptoms; DPD days post diagnosis; P-NT50 pseudovirus neutralization test 50% inhibition titer; VNT50 virus neutralization test 50% inhibition titer; ND, not determined; 95% CI